Abstract:Background Diabetic cardiovascular complication is a major cause of mortality in type 2 diabetic patients. Hyperglycemia markedly increases the risk of cardiovascular disease. Endothelial dysfunction is common in type 2 diabetes mellitus (DM) and is an early indicator of diabetic vascular disease. Therefore, it is necessary to identify the effect of different hypoglycemic agents on vascular endothelium. The aim of the study was to examine and compare the effects of metformin and gliquidone on atherosclerotic lesions in streptozotocin-induced diabetic rats. Methods Forty male Sprague-Dawley rats (age, 8 weeks; weight, 180–200 g) were included in this study and fed with a normal chow diet for 1 week. Rats (n=10) served as the normal control group (NC group) were fed with a normal chow for another 2 weeks and received an injection of saline. The rest 30 rats fed with a high-fat diet for 2 weeks and injected streptozotocin were randomly assigned to three groups (n=10 rats per group) as follow: type 2 DM group (DM group), DM + gliquidone group (GLI group) and DM + metformin group (MET group). Five weeks later, all rats were fasted overnight and taken tail blood samples for biochemical determinations. Then rats in the NC and DM groups were administrated with normal saline, while rats in the MET and GLI groups were administrated with metformin (100 mg/kg) or gliquidone (10 mg/kg), respectively. All medicines were given via intragastric administration for 8 weeks. After 16 weeks, plasma triglyceride (TG), total cholesterol (TC), low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C) were measured. The aortic arch was isolated from diabetic rats and was assessed by pathological sectioning using H&E staining. Results Metformin treatment prevented weight gain ((315.80±52.16) g vs. (318.70±68.48) g, P=0.773), improved plasma TG, HDL-C and LDL-C levels (P=0.006, 0.003, 0.001, respectively, all P <0.05). However, gliquidone showed no significant effects on plasma TG and TC levels (P=0.819, 0.053, respectively). LDL-C and HDL-C in the GLI group changed ((0.46±0.10) mmol/L vs. (0.36±0.14) mmol/L, P=0.007; (0.99±0.27) mmol/L vs. (1.11±0.18) mmol/L, P=0.049). Both metformin and gliquidone treatment lowered blood glucose levels (P=0.001, 0.004, respectively, P <0.05). Under light microscopy, no changes were observed in the aortic wall structure of each layer; the intima was smooth and the membrane elastic fibers were normal in the NC group. In the DM group, the aortic wall structure was unclear, the intima was thickened with irregular intima, and membrane elastic fibers collapsed. The aortic intima in the MET and GLI groups was smoother compared with the DM group, but the endothelial structure of the MET group was closer to that of the NC group. Conclusions Both metformin and gliquidone have anti-atherosclerotic effects. But the endothelial structure of the MET group was closer to that of the NC group. Metformin and gliquidone therapy can reduce serum level of LDL-C and increase level of HDL-C, whereas gliquidone therapy did not lose weight and decrease serum level of TG. These data may have important implications for the treatment of patients with type 2 DM.

Effects of Metformin and Sitagliptin on Glycolipid Metabolism in Type 2 Diabetic Rats on Different Diets.

Gliquidone Versus Metformin: Differential Effects on Aorta in Streptozotocin Induced Diabetic Rats

Transcriptomic and Proteomic Analysis of Potential Therapeutic Target Genes in the Liver of Metformin‑treated Sprague‑Dawley Rats with Type 2 Diabetes Mellitus

Lipid Profiling Reveals Different Therapeutic Effects of Metformin and Glipizide in Patients with Type 2 Diabetes and Coronary Artery Disease

Effects of Metformin and Sitagliptin Monotherapy on Expression of Intestinal and Renal Sweet Taste Receptors and Glucose Transporters in a Rat Model of Type 2 Diabetes

Effects of metformin, acarbose, and sitagliptin monotherapy on gut microbiota in Zucker diabetic fatty rats

Efficacy of Adding Sitagliptin to Ongoing Metformin on Metabolic Profile, Triglyceride-Glucose Index, Vitamin D3, and Liver Tests in Patients Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease: A Double-Blind Randomized Clinical Trial

Comparative Evaluation of the Effect of Metformin and Insulin on Gut Microbiota and Metabolome Profiles of Type 2 Diabetic Rats Induced by the Combination of Streptozotocin and High-Fat Diet

Effects of sitagliptin combined with metformin for type 2 diabetes mellitus: a meta-analysis

Effect of Sitagliptin Versus Glibenclamide on Glycemic Markers, Lipid Profile Inflammatory and Oxidative Stress Factors in Type 2 Diabetes Patients: a Double-Blinded Randomized Controlled Trial

Effects of Dapagliflozin and Sitagliptin on Insulin Resistant and Body Fat Distribution in Newly Diagnosed Type 2 Diabetic Patients

The Beneficial Effect Of Metformin On Beta-Cell Function In Non-Obese Chinese Subjects With Newly Diagnosed Type 2 Diabetes

Effects of metformin on the glucose regulation, lipid levels and gut microbiota in high-fat diet with streptozotocin induced type 2 diabetes mellitus rats

Influence of Pioglitazone or Metformin on Insulin Resistance in Patients with Type 2 Diabetes Mellitus

Effects of sitagliptin on intrahepatic lipid content in patients with non-alcoholic fatty liver disease

Effects of metformin, saxagliptin and repaglinide on gut microbiota in high-fat diet/streptozocin-induced type 2 diabetic mice

Effects of Sitagliptin as Monotherapy and Add-On to Metformin on Weight Loss among Overweight and Obese Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis

Antiatherosclerosis effect of sitagliptin in patients with type 2 diabetes mellitus

The Effect of Canagliflozin on High-Density Lipoprotein Cholesterol and Angiopoietin-Like Protein 3 in Type 2 Diabetes Mellitus

Effects of Sitagliptin Treatment on Dysmetabolism, Inflammation, and Oxidative Stress in an Animal Model of Type 2 Diabetes (ZDF Rat)

Metabolic effects of SGLT2i and metformin on 3-hydroxybutyric acid and lactate in db/db mice